Botanical and Plant-Derived Drugs: Global MarketsReport Details:Published:January 2013No. of Pages: 143Price: Single User License – US$5450REPORT HIGHLIGHTSThis report provides:•An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward•Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017•A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall "wellness" rather than to address a specific medical condition or symptoms)•Examination of the industry structure, competition, and market drivers•Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area•Observations and conclusions regarding the future of the botanical and plant-derived drug industry Comprehensive company profiles of major players.REPORT SCOPEINTRODUCTIONSTUDY BACKGROUNDBecause the use of plant-derived drugs has become so widespread, there is a great need todevelop an up-to-date base of market information about these products. More than four yearshave passed since BCC Research published its first version of Botanical and Plant-Derived Drugs:Global Markets. This report is an update of that one. Both analyze the key growth areas in plant-derived drugs, develop quantitative market projections and discuss compliance with therequirements for the botanical category of drugs, created in 2004, with its own U.S. FDAregulations, guidelines and review process.STUDY GOAL AND OBJECTIVESThe present study meets this need by focusing on the global market for plant-derived drugs in lightof the most recent available information. In addition to looking at future and current markets for awide variety of new, reformulated and established products, the study will analyze technological,environmental, legal/regulatory and socioeconomic developments that may influence the marketfor plant-derived drugs.
This report provides an analysis of the emerging botanical drug industry and markets,geographically and by therapeutic area. The future of plant-derived drugs as a whole is discussed.More specific objectives are as follows:•Identify and classify the botanical and plant-derived drugs that have been commercialized to date.•Identify and evaluate the impact of factors that will drive future demand for botanical drugs with a focus too on plant-based drugs overall.•Forecast the volume and value of shipments of botanical drugs through 2017.•Describe botanical drugs that are currently in clinical testing or the approval stage and assess the probability that they will be commercialized successfully in the next five years.•Forecast the potential market for these drug candidates, weighted to reflect the estimated probability that they will be commercialized.•Identify the leading manufacturers of plant-derived drugs and the firms that may become important players in the next five years.•Assess the long-term outlook for the plant-derived drug industry, taking into account market opportunities as well as technological, environmental, legal/regulatory and socioeconomic factors.INTENDED AUDIENCEThe report has been written for the entire pharmaceutical community, but is tailored especially forreaders with an interest in the marketing, management and public policy dimensions of botanicaldrugs, including readers in the following:•The pharmaceutical industry, especially companies supplying bulk or formulated plant-derived drugs or companies that are planning to enter this field.•Medical research institutions.•International organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade.•Investors.•The financial and analyst community.SCOPE OF REPORTThis report is an analytical business tool whose primary purpose is to describe the botanical drugindustry with the overall plant-derived drug industry as a backdrop and the global market for thesedrugs going forward.For the purposes of this report, botanicals are those drugs that are FDA-approved under thebotanical drug pathway, while plant-derived drugs are both botanicals as well as other approveddrugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.The studys main focus is on legal, prescription-required therapeutic medicines sold in the openmarket. The study does not specifically cover herbals generally sold as dietary supplements (i.e.,to promote overall "wellness" rather than to address a specific medical condition or symptoms).While there is a substantial market for these products, the medical value of many of thesesubstances has not been demonstrated conclusively.The study also does not cover the following:•Underground or illicit drugs.•Home remedies.
•Tribal medicines.•Drugs derived from Archaea, bacteria and fungi (molds and yeasts).•Non-medicinal plant substances such as laxative cellulose and pectin fiber.•Intravenously delivered nutrients of plant origin, such as dextrose.•Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.•Plant substances serving in cosmetics, toiletries and personal care products.•Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.•Marine life.The format of the study is organized around the following topics:•Major types and applications of botanical drugs with plant-derived drugs as their backdrop.•Industry structure.•Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.•Market drivers.•Market projections through 2017.•Competition.•Observations and conclusions regarding the future of the botanical and plant-derived drug industry.METHODOLOGY AND INFORMATION SOURCESBoth primary and secondary research methods were used in preparing this research report. Thefindings and conclusions contained in this report are based on information gathered fromdevelopment companies and sales and manufacturers involved with primarily, botanical drugs asdefined by the U.S. FDA and secondarily, the larger world of plant-derived drugs, whichencompasses botanical drugs as a subsegment. Additional data were obtained from extensivereviews of secondary sources such as trade publications, trade associations, company literatureand online databases.COMMERCIAL DRUGSIn the case of commercial drugs, the study starts by projecting the demand for various types ofmedical applications, such as chemotherapy drugs, asthma and medicine, which use plant-deriveddrugs as part of the therapy. The implied demand for plant-derived drugs is then estimated basedon historical relationships, adjusted to reflect such factors as the availability of alternative, non-plant-derived drugs; price relationships; and other buyer criteria as well as other information fromrelevant companies.DEVELOPMENTAL DRUGSThe approach described above is useful mainly for drugs that are already in commercial use. Asomewhat different approach is used to project demand for drugs that are still in the developmentor regulatory testing and approval processes, but are expected to be commercialized in the 2012to 2017 time frame.In some cases, a new plant-derived drugs developers or other industry analysts are projectingthat the drug will be commercialized by a particular year (e.g., 2017). Where this is not the case,
BCC uses the timeline for the U.S. FDA approval process as a yardstick for evaluating thelikelihood that a particular plant-based drug will be commercialized in the next five years. (Even incases where developers are projecting a particular year, BCC has used the FDA approval processtimeline as a kind of reality check.)In the United States, it takes 12 years, on average, for an experimental drug to complete clinicaltesting and receive FDA approval, as shown below.Since the market projections in this report include only products that are likely to becommercialized in the five-year period of 2012 to 2017, the projections are limited to plant-deriveddrug candidates that are likely to receive FDA approval by 2017. This in turn generally limits thefield of drugs that are in Phase III clinical trials or in the final FDA approval process.Get your copy of this report @http://www.reportsnreports.com/reports/213058-botanical-and-plant-derived-drugs-global-markets.htmlMajor points covered in Table of Contents of this report includeTABLE OF CONTENTSChapter- 1: INTRODUCTION - ComplimentarySTUDY BACKGROUNDSTUDY GOAL AND OBJECTIVESINTENDED AUDIENCESCOPE OF REPORTMETHODOLOGY AND INFORMATION SOURCESCOMMERCIAL DRUGSDEVELOPMENTAL DRUGSANALYST CREDENTIALSRELATED BCC PUBLICATIONSBCC ONLINE SERVICESDISCLAIMERChapter- 2: SUMMARYTable Summary : GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS,THROUGH 2017Figure Summary : GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS,2010-2017Chapter- 3: OVERVIEWBRIEF HISTORY OF PLANT-DERIVED MEDICINESOPPORTUNITY LIES BEYOND WHAT IS KNOWNGETTING STARTEDKEY DRIVERSKEY CHALLENGESU.S. GOVERNMENT INVESTMENTINDUSTRY INVESTMENTBOTANICAL DRUGS DEFINEDUNDERSTANDING THE REGULATORY PROCESS
THE FIRST APPROVED BOTANICALBOTANICAL CANDIDATES IN THE PIPELINEA GROWING PIPELINEOVERALL PHARMA LANDSCAPEINTELLECTUAL PROPERTYPRODUCTIONSUPPLY AND LEGAL ISSUESChapter- 4: MARKET SEGMENTATIONGEOGRAPHIC SEGMENTATIONTHERAPEUTIC AREA SEGMENTATIONChapter- 5: THERAPEUTIC AREAS FOR PLANT-DERIVED AND BOTANICAL DRUGSHORMONE THERAPY AND METABOLISM APPLICATIONSINFECTIOUS DISEASE APPLICATIONSPAIN AND CENTRAL NERVOUS SYSTEM DISEASE APPLICATIONSCARDIOVASCULAR AND METABOLIC DISEASERESPIRATORY, INFLAMMATION (BOTH NON-RELATED AND RELATED TO ORTHOPEDIC)AND AUTOIMMUNEDERMATOLOGY APPLICATIONSGASTROINTESTINAL APPLICATIONSONCOLOGY APPLICATIONSChapter- 6: COMPANY PROFILESABBOTT LABORATORIESADVANCED LIFE SCIENCESAMAREX CLINICAL RESEARCHAMERICAN ORIENTAL BIOENGINEERINGANALYTICON DISCOVERY GMBHARTECEF BVAVESTHAGEN INC.BAYER HEALTHCARE PHARMACEUTICALSBEIJING PEKING UNIVERSITY WBL BIOTECH CO. LTD.BIONORICA SEBIONUMERIK PHARMACEUTICALS INC.BIONOVO INC.BOEHRINGER INGELHEIMBOTANICAL DRUG CORP.BRISTOL MYERS SQUIBBCARDAX PHARMACEUTICALSCHI-MEDCHINA BOTANIC PHARMACEUTICALCHONG KUN DANG PHARMACEUTICAL CORP.CUBIST PHARMACEUTICALS INC.CURAPHARM INC.
SCHWABE PHARMACEUTICALSSE-CURE PHARMACEUTICALS LTD.SEQUOIA SCIENCES INC.SIRTRISSUNTEN PHYTOTECH CO. LTD.TASLY PHARMACEUTICALS INC.TCM BIOTECH INTERNATIONAL CORP.VEDIC LIFESCIENCES PVT. LTD.VIROXISVR LABORATORIES LLCZHEJIANG KANGLAITE GROUP CO LTD.Chapter- 7: APPENDIXTable 26 : PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONSTable 27 : USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRYLIST OF TABLESTable A : FDA APPROVAL PROCESS FOR NEW DRUGSSummary Table : GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS,THROUGH 2017Table 1 : KEY DATES IN BOTANICAL MEDICINETable 2 : WELL KNOWN PLANT-DERIVED DRUGSTable 3 : SWOT ANALYSIS OF BOTANICAL DRUG DEVELOPMENTTable 4 : KEY INVESTMENTS IN BOTANICAL AND OTHER PLANT-DERIVED DRUGSTable 5 : DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLYTable 6 : BOTANICAL COMPOSITION OF MENERBA (MF 101)Table 7 : TOP PHARMA COMPANIES BY SALES, 2011Table 8 : MAJOR UPCOMING U.S. PATENT EXPIRIES, 2012-2016Table 9 : MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALSTable 10 : KEY COMPANIES WITH NATURAL PRODUCT LIBRARIESTable 11 : FDA APPROVED BOTANICAL DRUGS FORECAST, THROUGH 2017Table 12 : RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BYTHERAPEUTIC AREA, THROUGH 2017Table 13 : PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATESTAGE DEVELOPMENTTable 14 : PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENTTable 15 : BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGSTable 16 : PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENTTable 17 : PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGEDEVELOPMENTTable 18 : PLANT-DERIVED RESPIRATORY, INFLAMMATION (BOTH NON-RELATED ANDRELATED TO ORTHOPEDIC) AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENTTable 19 : PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGEDEVELOPMENT
Table 20 : PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE* DEVELOPMENTTable 21 : ESTIMATED U.S. CANCER CASES BY GENDER, 2012Table 22 : PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENTTable 23 : BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH POSSIBLE FDA-APPROVED COMMERCIALIZATION, THROUGH 2017*Table 24 : PHYNOVA PIPELINETable 25 : SUNTECH PHYTOTECH PIPELINETable 26 : PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONSTable 27 : USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRYLIST OF FIGURESSummary Figure : GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS,2010-2017Figure SAMPLE FIGURE : GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVEDDRUGS, 2010-2017Figure 1 : TYPE OF NATURAL PRODUCT DRUGS SUBMITTED AS IND APPLICATIONS TOTHE FDA, 2008Figure 2 : THERAPEUTIC AREAS OF FDA DRUG APPROVALS, 2011Figure 3 : SNAPSHOT OF U.S. FDA BOTANICAL PIPELINE, 2011Figure 4 : PHARMA DRUG SALES BY REGION, 2011 AND 2016Figure 5 : COMPOSITION OF FDA APPROVED BOTANICAL INDICATIONS FORECAST BYTHERAPEUTIC AREA, 2012 AND 2017Figure 6 : RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BYTHERAPEUTIC AREA, 2012 AND 2017Contact: firstname.lastname@example.org for more information.